
    
      This is an event driven study to reach statistical power given all other assumptions.
      Subjects will visit the clinic 1 month after randomization and at regular intervals
      thereafter. Additionally, for any subject prematurely discontinuing study medication,
      assessments will be conducted every 6 months for the collection of study endpoints.

      Those who are likely to qualify will undergo Genotype Assay Testing to evaluate genetic
      determination or the presence of the AA genotype. The test is investigational and test
      procedures are Roche Molecular Diagnostics protocol ADCY9-COB-389.
    
  